Thursday, July 31, 2014
A mutation in isocitrate dehydrogenase 1 commonly found
in gliomas alters
the enzyme's conformation and triggers pathways that lead to the disease. A
Heidelberg group has developed a peptide vaccine that distinguishes mutant from
normal enzyme and reduces tumor size in mice.1 The team is hoping
the vaccine could join the race for a glioma immunotherapy but needs to show
that it can generate enough neo-antigen-specific T cells and antibodies to spark
an effective immune response in patients.
To investigate the immunogenic potential of mutant IDH1,
the Heidelberg team created peptide libraries that included the region
containing the R132H mutation and the corresponding wild-type residue of IDH1.
Immune response jump-start
Pramod Srivastava told SciBX
that although patients had a low endogenous immune response rate to mutant
IDH1, the key question is whether a mutant IDH1-based vaccine could jump-start
the immune system to augment that response. According to Srivastava, the next
step for the researchers should be to test the vaccine in patients-although he
noted several possible pitfalls.
Baas, T. SciBX 7(29);
Published online July 31, 2014
1. Schumacher, T. et
al. Nature; published online June 25, 2014; doi:10.1038/nature13387
Contact: Michael Platten, German Cancer Research Center, Heidelberg,
(NASDAQ:AGEN), Lexington, Mass.
Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass.
Celldex Therapeutics Inc.
(NASDAQ:CLDX), Needham, Mass.
German Cancer Research Center, Heidelberg, Germany
Heidelberg University Hospital, Heidelberg, Germany
immatics biotechnologies GmbH, Tuebingen, Germany
Stemline Therapeutics Inc. (NASDAQ:STML),
New York, N.Y.
University Hospital of Geneva, Geneva, Switzerland
University of California, San Francisco, Calif.
University of Connecticut Health Center, Farmington, Conn.